Mr. Hogan wrote in a letter to legislators that permanent funding for the board “would raise taxes and fees at a time when many are already out of work and financially struggling,” adding that doing so would be “unconscionable” during the pandemic.
Supporters of the board argued that Mr. Hogan’s veto is counteractive, as the board planned to lower drug costs and create more state funding through fees on drugmakers, insurers and pharmacy benefit managers.
Van Mitchell, the board’s chair, told STAT that they are moving forward with initial plans because the state already appropriated $750,000 this year to begin action.
More articles on pharmacy:
CVS’ goal of opening 1,500 HealthHubs on track despite pandemic
FDA adds heartburn drug being tested to treat COVID-19 to shortage list
Drug transport costs jump 224% amid COVID-19 pandemic, survey finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.